CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA

Federica Riccardo, Selina Iussich, Lorella Maniscalco, +16

Clinical Cancer Research

Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species

Giulio Ferrero, Francesca Cordero, Sonia Tarallo, +11

Oncotarget

Healthy IndividualsEngineeringGeneticsPathologyTranscriptomics Technology +16

Novel insights into Notum and glypicans regulation in colorectal cancer

Mariangela De Robertis, Maddalena Arigoni, Luisa Loiacono, +8

Oncotarget

miR-135b Coordinates Progression of ErbB2-Driven Mammary Carcinomas through Suppression of MID1 and MTCH2

Maddalena Arigoni, Giuseppina Barutello, Federica Riccardo, +10

American Journal Of Pathology

Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences

Anna Valentino, Anna Calarco, Anna Di Salle, +9

Oncogene

UrologyNon-coding RnaLong Non-coding RnaPathophysiological ConsequencesSmall Rna +6

Prolongation of survival of dogs with oral malignant melanoma treated by<i>en bloc</i>surgical resection and adjuvant<scp>CSPG4</scp>‐antigen electrovaccination

Lisa Adele Piras, Federica Riccardo, Selina Iussich, +15

Veterinary and Comparative Oncology

VaccinationVeterinary VaccineSurgical OncologyMedicineOral Malignant Melanoma +13

Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers

Federica Riccardo, Maddalena Arigoni, Genny Buson, +12

BMC Genomics

The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis

Silvio Bandini, Marco Macagno, Albana Hysi, +10

OncoImmunology

Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer

Laura Conti, Elisabetta Bolli, Antonino Di Lorenzo, +8

Cancer Immunology Research

Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy

Antonino Di Lorenzo, Elisabetta Bolli, Roberto Ruiu, +11

OncoImmunology